Form 4: OptimizeRx CEO Reports Routine Stock Transactions

OptimizeRx CEO Stephen L. Silvestro reported the acquisition of common stock from RSU conversion and a related tax withholding disposition.

Summary

• Stephen L. Silvestro, Chief Executive Officer of OptimizeRx Corp (OPRX), reported transactions on December 19, 2025.
• Acquired 6,546 shares of common stock through the conversion of restricted stock units (RSUs) at a price of $0.
• Disposed of 1,594 shares of common stock at $13.51 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, the CEO directly owns 193,868 shares of common stock.
• The restricted stock units vest in three equal annual installments, with the first vesting on December 19, 2024.

Sentiment

Score: 5

Explanation: The filing is a routine Form 4 reporting scheduled equity compensation transactions (RSU vesting and tax withholding), which are neutral in sentiment. It reflects standard corporate governance and executive compensation practices.

Positives

• The acquisition of 6,546 shares of common stock through RSU conversion indicates continued equity participation and alignment of management interests with shareholders.

Negatives

• The disposition of 1,594 shares was solely for tax withholding purposes, which is a routine event upon RSU vesting and not indicative of a negative outlook.

Future Outlook

The filing indicates a pre-planned transaction under Rule 10b5-1(c), suggesting a structured approach to equity compensation and tax management for the CEO.

Industry Context

This is a routine insider transaction filing, common for executives receiving equity compensation. It reflects standard practice for vesting restricted stock units and managing associated tax obligations, rather than a strategic market move.

Stakeholder Impact

• Shareholders: The transactions reflect the CEO's continued equity ownership and alignment with shareholder interests through long-term incentive plans.
• Employees: The RSU vesting is part of a standard executive compensation package, which can serve as a model for broader employee incentive programs.

Next Steps

• Future vesting installments of restricted stock units will occur annually following December 19, 2024.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to equity compensation (RSU vesting and tax withholding). It does not provide new fundamental information about the company's performance, strategy, or outlook that would warrant a change in investment recommendation. The transactions are expected and pre-planned, indicating no significant shift in management's view or company prospects. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific filing.

Keywords

OptimizeRx, OPRX, Stephen L. Silvestro, CEO, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, RSU Conversion, Tax Withholding